This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nowell, S. Articles by Lang, N. P. Search for Related Content PubMed PubMed Citation Articles by Nowell, S. Articles by Lang, N. P.

CYP2A6 Activity Determined by Caffeine Phenotyping

Association with Colorectal Cancer Risk¹

Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock 72205 [S. N.]; Department of Surgical Oncology [N. P. L., C. S., S. N.], Central Arkansas Veteran’s Health Care System [N. P. L.], Little Rock 72205; and National Center for Toxicological Research, Jefferson 72079 [F. F. K., C. S., G. H.], Arizona

Cytochrome P450 2A6 (CYP2A6) catalyzes the metabolic activation of several procarcinogens including dietary and environmental nitrosamines, and the involvement of CYP2A6 in cancer development has been postulated. CYP2A6 phenotype was determined using caffeine as a probe drug in individuals participating in a case-control study of colorectal cancer (127 cases and 333 controls matched on age, gender, race, and geographic region). Conversion of the caffeine metabolite 1,7-dimethylxanthine (17X) to 1,7-dimethyl uric acid (17U) is catalyzed primarily by CYP2A6, and this activity can be assayed by comparison of urinary molar ratios of metabolites. Caffeine (200 mg) was administered to each participant, and a 4–5 h postadministration urine sample was collected. Urinary metabolites of caffeine were separated by high-performance liquid chromatography and quantified by comparison to authentic standards. We examined the distributions of the ratio, 17U:17X, according to subject characteristics among controls. In case-control comparisons, subjects in the medium and high tertiles of CYP2A6 activity had an increased risk of colorectal cancer compared with subjects with low activity. Odds ratios from a conditional logistic regression model for medium and high 17U:17X ratio were 2.0 (95% confidence interval, 1.1–3.7) and 2.6 (95% confidence interval, 1.5–4.5), respectively (P for trend = 0.001). CYP2A6 phenotype has not been compared previously between cancer cases and controls. We found a strong relationship between CYP2A6 activity, measured by urinary caffeine metabolite ratio, and colorectal cancer risk.

This article has been cited by other articles:

				K. S. Derby, K. Cuthrell, C. Caberto, S. G. Carmella, A. A. Franke, S. S. Hecht, S. E. Murphy, and L. Le Marchand Nicotine Metabolism in Three Ethnic/Racial Groups with Different Risks of Lung Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3526 - 3535. [Abstract] [Full Text] [PDF]

				B Sinues, A Fanlo, E Mayayo, C Carcas, J Vicente, I Arenaz, and A Cebollada CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives Human and Experimental Toxicology, May 1, 2008; 27(5): 367 - 372. [Abstract] [PDF]

				M. H. Ward, A. J. Cross, H. Divan, M. Kulldorff, S. Nowell-Kadlubar, F. F. Kadlubar, and R. Sinha Processed meat intake, CYP2A6 activity and risk of colorectal adenoma Carcinogenesis, June 1, 2007; 28(6): 1210 - 1216. [Abstract] [Full Text] [PDF]

				M. Kimura, H. Yamazaki, M. Fujieda, K. Kiyotani, G. Honda, J. Saruwatari, K. Nakagawa, T. Ishizaki, and T. Kamataki CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS Drug Metab. Dispos., September 1, 2005; 33(9): 1361 - 1366. [Abstract] [Full Text] [PDF]

				J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF]

				D. G. Covell, A. Wallqvist, A. A. Rabow, and N. Thanki Molecular Classification of Cancer: Unsupervised Self-Organizing Map Analysis of Gene Expression Microarray Data Mol. Cancer Ther., March 1, 2003; 2(3): 317 - 332. [Abstract] [Full Text] [PDF]